Prognostic implications of risk definitions from the monarchE and NATALEE trials

9 Просмотры

  • Спасибо! Поделитесь с друзьями!

    Вам не понравилось видео. Спасибо за то что поделились своим мнением!

admin
Издатель
In this latest episode of the VJOncoAlert Journal Club, Luca Arecco, MD, University of Genova, Genova, Italy, comments on the prognostic implications of risk definitions from the monarchE (NCT03155997) and NATALEE (NCT03701334) trials, highlighting the importance of standardized definitions for selecting optimal adjuvant endocrine therapy in hormone receptor-positive early breast cancer patients at high risk of recurrence. Dr Arecco presents findings from an analysis of individual patient-level data from three large adjuvant phase three clinical trials, showing significant differences in seven-year overall survival between patients classified as high risk by both trials, concordant low-risk, and discordant risk cohorts.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Категория
Рак Молочной Железы
Комментариев нет.

Следующее